Dr. Mingnan Chen and Group Receive R01 Grant From The National Institute of Allergy and Infectious Diseases
In January 2019, Dr. Mingnan Chen’s research group was awarded a R01 grant support ($ 2.7 million) from the National Institute of Allergy and Infectious Diseases to develop a precision immune cell-ablation therapy for autoimmune diseases. The ablation therapy, when translated to clinics, is expected to be more effective than current therapies for its broadly covering pathogenic cells. The new therapy will also likely avoid immunodeficiency that often plagues current therapies. This five-year project, together with the multidisciplinary research team led by Dr. Chen, will provide research and training opportunities to graduate students of Department of Pharmaceutics and Pharmaceutical Chemistry at the interface of protein engineering, immunology, and pharmaceutics. The grant application that leads to this award received a 2-percential ranking at a NIH study section. The core collaborators of this awarded project are Dr. Robert Fujinami (Microbiology and Immunology), Dr. Simon Fisher (Endocrinology and Metabolism), and Dr. Yue Zhang (Epidemiology) at the University of Utah.
